Reporting
Download our latest reports
Annual Report 2023
Half-Year Report 2024
Annual report 2023
Our management
in conversation
Continued strong
growth trajectory
0.000
Increase: +3.4%
0.0
Increase: +0.3%
0.0
Increase: +0.6%
0.0
Increase: +0.3%
The year 2023 in review
March: Opening Development Center Barcelona
Siegfried opens global Development Center for Drug Products in Barcelona.
April: Annual General Meeting
Siegfried increases distribution and appoints Elodie Carr-Cingari to the Board of Directors, thus strengthening diversity at the highest level.
April: Start construction of R&D Center DS in Evionnaz
Siegfried begins construction of a new global R&D Center for Drug Substances in Evionnaz.
May: Acquisition of DINAMIQS
Siegfried acquires majority stake in DINAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies.
May: Anniversary celebration
Siegfried celebrates its 150th anniversary with a big party and looks back on its long, eventful history.
May: Announcement Henrik Krüpper
Siegfried announces Henrik Krüpper as the new COO Drug Substances.
December: Dow Jones Sustainability Index Europe
Siegfried confirmed in the Dow Jones Sustainability Index Europe for the third consecutive year.
December: Energy savings
Siegfried implemented electricity savings projects equivalent to 18 GWh/year (3400 average households in Switzerland).